Immunotherapy for All

This debate will contrast broad use of immunotherapy with molecular profiling-guided individualized approaches in frontline care for metastatic endometrial cancer. Evaluate clinical trial data supporting immunotherapy across patient populations alongside evidence for tailoring therapy based on molecular subtypes, reviewing practical considerations in applying these strategies in routine practice. Speakers will illuminate how evolving data are reshaping personalized care in endometrial cancer care. Faculty will review key clinical trial data supporting immune-based regimens, including outcomes across molecular and histologic subtypes, and address patient selection, toxicity management, and integration of immunotherapy into current treatment algorithms. Participants will explore the expanding role of immunotherapy in improving outcomes for patients.